To explore the clinical efficacy of Badu Shengji Powder in the treatment of chronic refractory wounds.Methods:China National Knowledge Infrastructure(CNKI)，China Science Periodical Database(CSPD)，Chinese Citation Database(CCD)，China Biology Medicine(CBM)，American Medicine Database(Medicine)，and the Cochrane Library were searched for clinical randomized controlled trials(RCTs) on the efficacy of Badu Shengji Powder in treating chronic refractory wounds by keywords from database inception to October 2022.After two investigators screened the literature in accordance with inclusion and exclusion criteria，extracted the data，and evaluated the risk of bias of included studies，RevMan5.3 software was used for systematic evaluation and Meta-analysis.Results:Fourteen RCTs were included，with 787 patients involved，i.e.，394 patients in the treatment group and 393 patients in the control group.Meta-analysis showed that the wound healing rate in the treatment group was higher than that in the control group(OR=4.08，95%CI 2.55 to 6.55，P<0.000 01).The effective rate of wounds in the treatment group was higher than that in the control group(OR=6.08，95%CI 3.45 to 10.73，P<0.000 01).The wound healing time in the treatment group was shorter than that in the control group(MD=-3.07，95%CI -4.12 to -2.03，P<0.000 01).The pain score of the treatment group was lower than that of the control group(MD=-1.18，95%CI -2.03 to -0.33，P＝0.006).Conclusion:The current evidence shows that the clinical application of Badu Shengji Powder can improve the healing rate of chronic refractory wounds and the effective rate，shorten the healing time of wounds，and relieve pain.However，due to the limitations of the studies included，the above conclusion still needs more high-quality research validation.